A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) with Lu-Edotreotide Compared to Targeted Molecular Therapy with Everolimus